📘

Definitions

1

DELTA-P score for small-cell lung carcinoma prediction in LEMS

A clinical score that allocates one point for each of a set of features present at or within three months of onset, to estimate the probability that a patient with LEMS has an underlying small-cell lung carcinoma and so to set the intensity of tumour screening. Seven independent predictors of small-cell lung carcinoma were identified: age at onset, smoking behaviour, weight loss, Karnofsky performance status, bulbar involvement, male sexual impotence, and SOX1 antibodies. The score built from them contains only six items, and the seventh is the one deliberately left out. SOX1 serology is excluded, so the maximum score is 6 and the instrument is purely clinical - which is what the source means by calling it "the simple clinical DELTA-P score", and what makes it usable at the bedside before any antibody result returns. The six scored items are age at onset at least 50 years, smoking at diagnosis, weight loss of at least 5%, bulbar involvement, erectile dysfunction, and Karnofsky performance status below 70, each present at or within three months of onset. Several are the disease's own phenotypes, which is what makes the score a mechanism-adjacent instrument rather than a generic risk calculator: the paraneoplastic form declares itself partly through a more aggressive neurological presentation.

PHENOTYPE_ALGORITHM

Show evidence (4 references)

PMID:21245427 SUPPORT Human Clinical

"We derived a prediction score for SCLC in LEMS in a nationwide cohort of 107 Dutch patients, and validated it in a similar cohort of 112 British patients"

The derivation and validation cohorts, which is what the VALIDATED_AGAINST_GOLD_STANDARD status rests on.

PMID:21245427 SUPPORT Human Clinical

"Age at onset, smoking behavior, weight loss, Karnofsky performance status, bulbar involvement, male sexual impotence, and the presence of Sry-like high-mobility group box protein 1 serum antibodies were independent predictors for SCLC in LEMS"

The seven independent predictors. Quoted because the distinction between these and the six scored items below is the thing most easily got wrong about this score - SOX1 appears here and not there.

PMID:21245427 SUPPORT Human Clinical

"A DELTA-P score was derived allocating 1 point for the presence of each of the following items at or within 3 months from onset: age at onset ≥ 50 years, smoking at diagnosis, weight loss ≥ 5%, bulbar involvement, erectile dysfunction, and Karnofsky performance status lower than 70"

The six items that are actually scored, with SOX1 absent. This is the operative definition of the instrument.

+ 1 more reference

?

Discussions and Knowledge Gaps

1

What accounts for the roughly one in ten patients with clinical and electrophysiological LEMS in whom P/Q-type VGCC antibodies are not detected?

KNOWLEDGE GAP OPEN gap_antibody_negative_lems

Attached to

pathophysiology#Anti-P/Q-Type VGCC Autoantibody Production

The cited review reports antibody detection in about 90% of patients, which leaves a seronegative remainder that the entry's mechanism does not explain. The possibilities are not equivalent and they are not distinguished by the evidence curated here: assay insensitivity for low-titre or conformation-dependent antibodies; antibodies against a different presynaptic target not covered by the standard assay; or a genuinely distinct presynaptic disorder sharing the phenotype. The second possibility is not merely speculative. In a series of 20 patients, six had antibodies against synaptotagmin, a synaptic vesicle protein rather than a calcium channel, and three of those six showed no cross-reactivity with any VGCC subtype at all. So antibodies to non-channel presynaptic proteins do occur in LEMS, and can occur without accompanying channel antibodies - which is the seronegative case this gap is about. What is not established is how much of the seronegative remainder they account for, since that study predates current assays and was not designed to sample it. Note what this does not affect. Tumour screening is driven by the DELTA-P score, which is purely clinical and contains no serology at all, so a VGCC-seronegative patient enters that pathway with nothing missing. SOX1 antibodies are a separate marker of the paraneoplastic form and a different antigen entirely - a nuclear SCLC tumour antigen, not the presynaptic calcium channel - so seronegativity for VGCC says nothing about SOX1 status either.

Proposed experiments

Antigen discovery in seronegative clinically defined LEMS

seronegative_lems_target_discovery

Screen serum from patients meeting clinical and electrophysiological criteria for LEMS but negative on standard P/Q-type VGCC radioimmunoassay against presynaptic terminal proteins, with passive transfer to test whether any candidate reproduces the release deficit.

Show evidence (3 references)

PMID:38494285 SUPPORT Human Clinical

"These antibodies can be detected in about 90% of patients"

Establishes the seronegative remainder this gap is about.

PMID:8583238 SUPPORT In Vitro

"Six patients' sera (1 with small cell lung carcinoma (SCLC)) contained antibodies specifically recognizing the recombinant synaptotagmin on immunoblots"

Antibodies to a non-channel presynaptic protein in LEMS, which is the second possibility this gap lists.

PMID:8583238 SUPPORT In Vitro

"Three of 6 synaptotagmin-positive sera had cross-reactivity with N and/or Q subtypes of VGCC; the remaining 3 showed no cross-reactivity with VGCCs"

The half of those sera with no channel reactivity at all - the closest thing in the cited literature to the seronegative case. PARTIAL because the study predates current assays and was not designed to quantify that remainder.

⚙

Pathophysiology

5

Small-Cell Lung Carcinoma Ectopic Antigen Expression and Anti-Tumour Immune Response

Half to two thirds of LEMS is paraneoplastic, and in those patients the tumour is not a comorbidity but the origin of the autoimmunity. Small-cell lung carcinoma is a neuroendocrine tumour that expresses neuronal antigens ectopically, and the immune response mounted against them cross-reacts with the same antigens at the presynaptic terminal. SOX1 is the clearest worked case: it was identified as a highly immunogenic SCLC tumour antigen, and antibodies against it are found in 64% of patients with LEMS and SCLC and in none with idiopathic LEMS. The clinical corollary is the one that makes this node worth curating separately. The anti-tumour response that produces the neurological disease also restrains the tumour: patients with SCLC-LEMS survive markedly longer than patients with SCLC alone. The autoimmunity is, on the tumour's terms, partly protective. Roughly 40-50% of LEMS has no tumour. This node is therefore a trigger for one form of the disease and absent in the other, and both converge on the antibody node below.

Downstream

Anti-P/Q-Type VGCC Autoantibody Production Cross-reactivity between the anti-tumour response and the neuronal channel. Curated with unknown intermediates because the evidence cached here establishes the tumour antigen, the antibody response and the association, but not the steps by which tolerance to the presynaptic channel is broken.

Show evidence (4 references)

PMID:38494285 SUPPORT Human Clinical

"Rapid diagnosis is important because of the association with SCLC in 50%-60% of patients, which stresses the need for vigorous tumor screening after diagnosis"

The frequency of the paraneoplastic form and the reason it drives the diagnostic pathway.

PMID:18032743 SUPPORT Human Clinical

"Probing of the fetal brain expression library with AGNA sera resulted in the isolation of SOX1, a highly immunogenic tumor antigen in SCLC"

Identifies a specific SCLC tumour antigen driving an antibody response in LEMS, which is the mechanism this node asserts.

PMID:18032743 SUPPORT Human Clinical

"SOX1 antibodies were present in 64% of patients with LEMS and SCLC but in none of the 50 with idiopathic LEMS (p < 0.0001)"

The all-or-none split between paraneoplastic and idiopathic LEMS, which is what licenses curating this as a trigger present in one form and absent in the other.

+ 1 more reference

Anti-P/Q-Type VGCC Autoantibody Production

Autoantibodies directed against P/Q-type voltage-gated calcium channels localised in the presynaptic motor nerve terminal and in the autonomic nervous system. Detectable in about 90% of patients. The shared distribution of the target across motor and autonomic terminals is the reason autonomic symptoms belong to this disease rather than accompanying it: one antigen, two systems. Quantitative autonomic testing bears this out - 93% of patients have an abnormal composite autonomic score, so dysautonomia is near-universal rather than occasional. One caveat belongs on the shared-antigen account rather than beside it. In the same series no autoantibody correlated with the severity of autonomic dysfunction, and the N-type channel antibodies that would be the obvious mediator of autonomic transmission were found in only a minority. The antigen is shared; the quantitative link between antibody and autonomic severity is not established.

calcium transport via high voltage-gated calcium channel GO:0061577 ↓ DECREASED

calcium ion transmembrane transporter activity GO:0015085 ↓ DECREASED

Downstream

Antigenic Modulation and Depletion of Active Zone Particles Bound antibody cross-links the channel, which is the step that removes it.

Show evidence (5 references)

PMID:38494285 SUPPORT Human Clinical

"P/Q-type voltage-gated calcium channels (VGCCs) localized in the presynaptic motor nerve terminal and in the autonomic nervous system are targeted by antibodies in LEMS patients"

Names the antigen and, in the same sentence, both tissues carrying it - which is what ties the autonomic arm to the motor one.

PMID:38494285 SUPPORT Human Clinical

"These antibodies can be detected in about 90% of patients"

The detection rate, which is what makes serology a practical diagnostic rather than a confirmatory afterthought.

PMID:9443463 SUPPORT Human Clinical

"Composite Autonomic Scoring Scale results were abnormal in 93% of patients, and autonomic failure was severe in 20%"

Quantitative autonomic testing showing that dysautonomia is near-universal, which is what the shared-antigen claim predicts.

+ 2 more references

Antigenic Modulation and Depletion of Active Zone Particles

The mechanism by which the antibody actually removes the channel, and the reason LEMS is a disease of channel number rather than of channel blockade. Bound divalent IgG cross-links the active zone particles - the freeze-fracture correlate of the presynaptic calcium channels - which aggregate into clusters and are then depleted from the membrane. The experiment that established this is a clean one. Divalent IgG and F(ab')2 fragments aggregate and deplete the particles; monovalent Fab, which binds the same epitope but cannot cross-link two channels, does nothing. The pathogenic step is therefore cross-linking rather than binding, which is why an antibody that merely occupied the channel would not produce this disease. Removal is partly compensated: the terminal homeostatically upregulates other calcium channel types, which is a candidate reason the clinical severity is not simply proportional to antibody titre.

calcium ion transmembrane transporter activity GO:0015085 ↓ DECREASED

presynaptic active zone GO:0048786

Animal models

LEMS IgG passive-transfer mouse Mouse recapitulates Passive transfer reproduces the channel loss and release-site disorganisation this node asserts, in an animal that never mounted the immune response itself.

Downstream

Reduced Calcium-Dependent Acetylcholine Release Fewer functional calcium channels at the active zone means less calcium entry per action potential, and transmitter release is a steeply nonlinear function of that entry.

Show evidence (3 references)

PMID:2853605 SUPPORT In Vitro

"Divalent LEMS IgG and F(ab')2 aggregated and depleted the active zone particles, whereas monovalent Fab had no effect"

The cross-linking requirement, with its own internal negative control. This is the specific claim the node makes.

PMID:2853605 SUPPORT In Vitro

"The active zone particles, normally arranged in double parallel rows, move closer together, form clusters, and are reduced in number"

The morphological consequence, observed by quantitative freeze-fracture electron microscopy.

PMID:29125190 SUPPORT Model Organism

"The LEMS-mediated attack reduces the number of presynaptic calcium channels, disorganizes transmitter release sites, and results in the homeostatic upregulation of other calcium channel types"

Independent confirmation in the passive-transfer model, and the source of the compensation claim in this node's description.

Reduced Calcium-Dependent Acetylcholine Release

Loss of functional presynaptic calcium channels reduces calcium influx on depolarisation, and acetylcholine release is steeply calcium-dependent. The result is a quantal release deficit at an otherwise intact neuromuscular junction: the postsynaptic receptor, the acetylcholinesterase and the muscle are all normal. Two clinical signs follow directly from this and from nothing else. Sustained or repeated activity transiently accumulates presynaptic calcium, which partially overcomes the deficit - so strength and reflexes briefly improve after exertion, the reverse of myasthenia gravis. And on repetitive nerve stimulation the same physiology produces an increment at high frequency against a decrement at low frequency, which the cited review reports as a highly sensitive diagnostic pairing.

motor neuron CL:0000100

acetylcholine secretion, neurotransmission GO:0014055 ↓ DECREASED

Downstream

Neuromuscular and Autonomic Transmission Failure

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"the presence of decrement and increment upon repetitive nerve stimulation is also a highly sensitive diagnostic test"

The electrophysiological signature of a presynaptic release deficit, quoted as the source states its diagnostic value.

Neuromuscular and Autonomic Transmission Failure

The clinical disorder: proximal weakness beginning in the upper legs, loss of tendon reflexes, and autonomic dysfunction. Progression can reach oculobulbar and, in severe cases, respiratory muscles. The ordering matters clinically. Weakness that starts in the thighs and spares the eyes early is the opposite of the ocular-onset pattern typical of myasthenia gravis, and it is a common reason LEMS is mistaken for a myopathy before serology is sent.

Show evidence (2 references)

PMID:38494285 SUPPORT Human Clinical

"Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disease characterized by proximal muscle weakness, loss of tendon reflexes, and autonomic dysfunction"

The defining triad in the source's own words.

PMID:38494285 SUPPORT Human Clinical

"Muscle weakness usually starts in the upper legs and can progress to oculobulbar and in severe cases respiratory muscles"

Establishes the proximal-onset pattern and the severe end of the range.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

8

Digestive 1

Bulbar Involvement Dysphagia HP:0002015

Show evidence (2 references)

PMID:38494285 SUPPORT Human Clinical

"Muscle weakness usually starts in the upper legs and can progress to oculobulbar and in severe cases respiratory muscles"

Bulbar progression as part of the natural history.

PMID:29125190 SUPPORT Human Clinical

"Occasionally, there is weakness in the face and sometimes in muscles that allow for chewing, swallowing, and breathing"

Names swallowing specifically, which is the phenotype bound here.

Eye 2

Ptosis HP:0000508

Show evidence (1 reference)

PMID:29125190 SUPPORT Human Clinical

"Like myasthenia gravis (MG), LEMS may also affect muscles of the eyelids, causing ptosis, and it occasionally affects muscles that move the eyes, resulting in diplopia, but these symptoms are usually mild"

States the phenotype and, in the same sentence, the severity qualifier that makes it a discriminator from myasthenia gravis.

Diplopia HP:0000651

Show evidence (1 reference)

PMID:29125190 SUPPORT Human Clinical

"it occasionally affects muscles that move the eyes, resulting in diplopia, but these symptoms are usually mild"

The phenotype with its frequency and severity qualifiers.

Head and Neck 1

Dry Mouth FREQUENT Xerostomia HP:0000217

Show evidence (2 references)

PMID:9443463 SUPPORT Human Clinical

"Dry mouth (77%) and impotence (45% of men) were the most common symptoms"

Direct quantitative support for the FREQUENT band (77%, within the 30-79% range), in a series of 30 patients with quantitative autonomic testing.

PMID:29125190 SUPPORT Human Clinical

"Involvement of the autonomic nervous system is also likely and may cause a dry mouth; sometimes erectile dysfunction is also present in men"

Names both autonomic phenotypes curated here in one sentence.

Musculoskeletal 1

Proximal Muscle Weakness HP:0003701

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"Muscle weakness usually starts in the upper legs"

The characteristic distribution.

Nervous System 1

Autonomic Dysfunction Abnormality of the autonomic nervous system HP:0002270

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"P/Q-type voltage-gated calcium channels (VGCCs) localized in the presynaptic motor nerve terminal and in the autonomic nervous system are targeted by antibodies"

Grounds the autonomic phenotype in the antigen's distribution rather than treating it as an unexplained association.

Other 2

Loss of Tendon Reflexes Hyporeflexia HP:0001265

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"characterized by proximal muscle weakness, loss of tendon reflexes, and autonomic dysfunction"

Establishes areflexia as a defining rather than incidental feature.

Erectile Dysfunction FREQUENT Autonomic erectile dysfunction HP:0008652

Show evidence (3 references)

PMID:9443463 SUPPORT Human Clinical

"Dry mouth (77%) and impotence (45% of men) were the most common symptoms"

Direct quantitative support for the FREQUENT band, at 45% of men.

PMID:29125190 SUPPORT Human Clinical

"Involvement of the autonomic nervous system is also likely and may cause a dry mouth; sometimes erectile dysfunction is also present in men"

The autonomic attribution, which is what the HPO term used here specifies.

PMID:21245427 SUPPORT Human Clinical

"Age at onset, smoking behavior, weight loss, Karnofsky performance status, bulbar involvement, male sexual impotence, and the presence of Sry-like high-mobility group box protein 1 serum antibodies were independent predictors for SCLC in LEMS"

Independent confirmation that the phenotype occurs in LEMS, in a cohort of 219 patients across two countries.

💊

Medical Actions

3

Amifampridine (3,4-Diaminopyridine)

Action: Pharmacotherapy NCIT:C15986

Agent: amifampridine CHEBI:135948

Potassium channel blocker that prolongs the presynaptic action potential, widening the window for calcium entry and so increasing acetylcholine release. It works downstream of the lesion without correcting it - the antibody is untouched. The efficacy trial used a randomised withdrawal design rather than a conventional placebo start, because the drug had been in use for thirty years without conclusive evidence and withholding it de novo was not acceptable. Patients stable on 3,4-DAP were tapered to placebo or continued: none of the 14 continued on drug deteriorated by more than 30% on timed up-and-go, against 72% of the 18 tapered to placebo.

Mechanism Target:

ACTIVATES Reduced Calcium-Dependent Acetylcholine Release — Increases release at the affected terminal by prolonging depolarisation. Curated as acting on the release node rather than on the antibody node, because it is symptomatic: it compensates for the deficit and does not reduce it.

Show evidence (2 references)

PMID:29280483 SUPPORT Human Clinical

"None of the 14 participants who received continuous 3,4-DAP had > 30% deterioration in 3TUG time versus 72% of the 18 who tapered to placebo (P < 0.0001)"

The primary efficacy result, with both arms and its denominators.

PMID:29280483 SUPPORT Human Clinical

"3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy"

Marked PARTIAL because it is context rather than support - it records why a withdrawal design was needed, which is what makes the result interpretable.

Tumour Treatment

Action: tumour-directed therapy Ontology label: Therapeutic Procedure NCIT:C49236

In paraneoplastic disease, treating the underlying small-cell lung carcinoma is part of treating the neurological disorder rather than a parallel concern. It is the only treatment in this entry that acts on the trigger rather than on the effector arm or the symptom, which is why it is curated separately from immunosuppression rather than bundled with it.

Mechanism Target:

INHIBITS Small-Cell Lung Carcinoma Ectopic Antigen Expression and Anti-Tumour Immune Response — Removing or shrinking the tumour removes the source of the ectopically expressed antigen that drives the cross-reactive response. Applies only to the paraneoplastic form; in tumour-negative LEMS this treatment has no target.

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"Treatment of the tumor as well as symptomatic treatment and immunosuppression can effectively control symptoms in the majority of patients"

Names tumour treatment as one of the three arms that control the neurological symptoms, which is the claim this edge makes.

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"Rapid diagnosis is important because of the association with SCLC in 50%-60% of patients, which stresses the need for vigorous tumor screening after diagnosis"

Why tumour screening, and therefore tumour treatment, is on the critical path in this disease rather than incidental to it.

Immunosuppression

Action: Immunosuppression Ontology label: Immunotherapy NCIT:C15262

Reduction of the pathogenic antibody, as opposed to compensating for its effect. Curated as acting on the antibody node rather than the release node, which is the distinction between it and amifampridine: one lowers the cause, the other works around it. The cached sources establish immunosuppression as an effective arm without specifying a regimen, so no specific agent is curated here. Corticosteroids, azathioprine, IVIG and plasma exchange are used in practice; adding them needs a reference in the cache that states the claim, which this entry does not yet have.

Mechanism Target:

INHIBITS Anti-P/Q-Type VGCC Autoantibody Production — Acts on production of the pathogenic autoantibody, upstream of the channel depletion and the release deficit.

Show evidence (1 reference)

PMID:38494285 SUPPORT Human Clinical

"Treatment of the tumor as well as symptomatic treatment and immunosuppression can effectively control symptoms in the majority of patients"

Establishes immunosuppression as an effective arm, which is what this edge asserts; the agent-level detail is deliberately not curated.

Show evidence (1 reference)

PMID:29125190 SUPPORT Human Clinical

"LEMS is an autoimmune disorder caused by antibodies directed against the voltage-gated calcium channels that provide the calcium ion flux that triggers acetylcholine release at the neuromuscular junction"

The rationale for an antibody-directed treatment. The antibody is the cause, so lowering it is disease-modifying in a way symptomatic treatment is not.

📊

Prevalence

1

United States national Veterans Affairs population

Point Prevalence 0.26 per 100,000 (0.26–0.33) 1–9 per 1,000,000

2.6 per 1,000,000 for confirmed cases and 3.3 per 1,000,000 including probable cases. The same study's crude prevalence estimates are higher (9.2 and 10.9 per 1,000,000); the point-prevalence figures are recorded here.

Show evidence (1 reference)

PMID:27997683 SUPPORT Human Clinical

"Point prevalence was estimated at 2.6 per 1,000,000 (confirmed cases) and 3.3 per 1,000,000 (combined confirmed and probable cases)"

The point-prevalence estimates quoted here, with their case definitions.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Lambert-Eaton Myasthenic Syndrome:

Myasthenia gravis

Overlapping Features The principal differential and the informative one. Both are autoimmune disorders of neuromuscular transmission, but the antigen sits on opposite sides of the synapse - postsynaptic acetylcholine receptor in myasthenia gravis, presynaptic calcium channel in LEMS. Separated by reflexes (lost in LEMS, preserved in myasthenia gravis), by the direction of the response to exertion, by autonomic involvement, and by the increment rather than decrement on high-frequency repetitive nerve stimulation.

Inflammatory or metabolic proximal myopathy

Overlapping Features Shares the proximal, leg-predominant weakness that typically brings LEMS patients to attention. Distinguished by intact tendon reflexes, absent autonomic features, and normal repetitive nerve stimulation.

🐁

Animal Models

1

LEMS IgG passive-transfer mouse

Daily intraperitoneal injection of LEMS patient serum or IgG into mice for two to four weeks. The model matters because it settles the direction of causation: the disease transfers with the antibody alone, so the antibody is sufficient and the cellular immune response is not required.

Species

Mouse

Publication

PMID:29125190

Pathograph links

Antigenic Modulation and Depletion of Active Zone Particles recapitulates fidelity: high Passive transfer reproduces the channel loss and release-site disorganisation this node asserts, in an animal that never mounted the immune response itself.

Limitations: Passive transfer models the effector arm and nothing upstream of it. It cannot reproduce the paraneoplastic trigger, tolerance breakdown, or the natural history, and the antibody is supplied continuously rather than produced.

Readouts

Presynaptic calcium channel number at the neuromuscular junction

Direction: DECREASED

Interpretation: The channel depletion this node models, produced by transferred human IgG.

Show evidence (1 reference)

PMID:29125190 SUPPORT Model Organism

"The LEMS-mediated attack reduces the number of presynaptic calcium channels, disorganizes transmitter release sites, and results in the homeostatic upregulation of other calcium channel types"

The measured channel loss and release-site disorganisation.

Show evidence (1 reference)

PMID:29125190 SUPPORT Model Organism

"a passive-transfer animal model has been developed in mice, which can be created by daily intraperitoneal injections of LEMS patient serum or IgG into mice for 2-4 weeks"

Establishes the model and its construction, which is what makes it informative for an antibody-effector node.

{ }

Source YAML

click to show

name: Lambert-Eaton Myasthenic Syndrome
creation_date: "2026-08-22T00:00:00Z"
category: Autoimmune
disease_term:
  preferred_term: Lambert-Eaton myasthenic syndrome
  term:
    id: MONDO:0018556
    label: Lambert-Eaton myasthenic syndrome
description: >-
  Autoimmune disorder of neuromuscular transmission caused by antibodies against
  presynaptic P/Q-type voltage-gated calcium channels, producing proximal weakness, loss
  of tendon reflexes and autonomic dysfunction.

  It is the presynaptic mirror of myasthenia gravis, and the contrast is what makes it
  mechanistically legible. Myasthenia gravis attacks the postsynaptic acetylcholine
  receptor, so the muscle cannot hear a normal signal; LEMS attacks the presynaptic
  calcium channel, so the nerve cannot send one. That single difference in locus predicts
  the entire clinical inversion - reflexes lost rather than preserved, weakness that
  briefly improves with exertion rather than worsening, autonomic involvement rather than
  none, and a drug that works by prolonging the nerve terminal action potential rather
  than by inhibiting acetylcholinesterase.

  In roughly half to sixty percent of patients it is paraneoplastic to small-cell lung
  carcinoma, so the diagnosis is also a cancer-screening trigger. That makes prediction
  of tumour risk a curated part of the disease rather than an afterthought.

pathophysiology:
- name: Small-Cell Lung Carcinoma Ectopic Antigen Expression and Anti-Tumour Immune Response
  role: trigger
  biological_scale: ORGANISM
  description: >-
    Half to two thirds of LEMS is paraneoplastic, and in those patients the tumour is not
    a comorbidity but the origin of the autoimmunity. Small-cell lung carcinoma is a
    neuroendocrine tumour that expresses neuronal antigens ectopically, and the immune
    response mounted against them cross-reacts with the same antigens at the presynaptic
    terminal. SOX1 is the clearest worked case: it was identified as a highly immunogenic
    SCLC tumour antigen, and antibodies against it are found in 64% of patients with LEMS
    and SCLC and in none with idiopathic LEMS.

    The clinical corollary is the one that makes this node worth curating separately. The
    anti-tumour response that produces the neurological disease also restrains the tumour:
    patients with SCLC-LEMS survive markedly longer than patients with SCLC alone. The
    autoimmunity is, on the tumour's terms, partly protective.

    Roughly 40-50% of LEMS has no tumour. This node is therefore a trigger for one form of
    the disease and absent in the other, and both converge on the antibody node below.
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rapid diagnosis is important because of the association with SCLC in 50%-60%
      of patients, which stresses the need for vigorous tumor screening after diagnosis"
    explanation: The frequency of the paraneoplastic form and the reason it drives the
      diagnostic pathway.
  - reference: PMID:18032743
    reference_title: "SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Probing of the fetal brain expression library with AGNA sera resulted in the
      isolation of SOX1, a highly immunogenic tumor antigen in SCLC"
    explanation: Identifies a specific SCLC tumour antigen driving an antibody response in
      LEMS, which is the mechanism this node asserts.
  - reference: PMID:18032743
    reference_title: "SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SOX1 antibodies were present in 64% of patients with LEMS and SCLC but in
      none of the 50 with idiopathic LEMS (p < 0.0001)"
    explanation: The all-or-none split between paraneoplastic and idiopathic LEMS, which is
      what licenses curating this as a trigger present in one form and absent in the other.
  - reference: PMID:31831596
    reference_title: "Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tumor survival was significantly longer in 81 patients with SCLC-LEMS
      compared to patients with non-LEMS SCLC (overall median survival 17 vs 7.0 months, p
      < 0.0001)"
    explanation: The anti-tumour arm of the same immune response, and the reason this node
      cannot be described purely as pathological.
  downstream:
  - target: Anti-P/Q-Type VGCC Autoantibody Production
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Cross-reactivity between the anti-tumour response and the neuronal channel. Curated
      with unknown intermediates because the evidence cached here establishes the tumour
      antigen, the antibody response and the association, but not the steps by which
      tolerance to the presynaptic channel is broken.
- name: Anti-P/Q-Type VGCC Autoantibody Production
  biological_scale: MOLECULAR
  description: >-
    Autoantibodies directed against P/Q-type voltage-gated calcium channels localised in
    the presynaptic motor nerve terminal and in the autonomic nervous system. Detectable
    in about 90% of patients.

    The shared distribution of the target across motor and autonomic terminals is the
    reason autonomic symptoms belong to this disease rather than accompanying it: one
    antigen, two systems. Quantitative autonomic testing bears this out - 93% of patients
    have an abnormal composite autonomic score, so dysautonomia is near-universal rather
    than occasional.

    One caveat belongs on the shared-antigen account rather than beside it. In the same
    series no autoantibody correlated with the severity of autonomic dysfunction, and the
    N-type channel antibodies that would be the obvious mediator of autonomic transmission
    were found in only a minority. The antigen is shared; the quantitative link between
    antibody and autonomic severity is not established.
  molecular_functions:
  - preferred_term: calcium ion transmembrane transporter activity
    term:
      id: GO:0015085
      label: calcium ion transmembrane transporter activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: calcium transport via high voltage-gated calcium channel
    term:
      id: GO:0061577
      label: calcium ion transmembrane transport via high voltage-gated calcium channel
    modifier: DECREASED
  downstream:
  - target: Antigenic Modulation and Depletion of Active Zone Particles
    causal_link_type: DIRECT
    description: >-
      Bound antibody cross-links the channel, which is the step that removes it.
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "P/Q-type voltage-gated calcium channels (VGCCs) localized in the presynaptic
      motor nerve terminal and in the autonomic nervous system are targeted by antibodies
      in LEMS patients"
    explanation: Names the antigen and, in the same sentence, both tissues carrying it -
      which is what ties the autonomic arm to the motor one.
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These antibodies can be detected in about 90% of patients"
    explanation: The detection rate, which is what makes serology a practical diagnostic
      rather than a confirmatory afterthought.
  - reference: PMID:9443463
    reference_title: "Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Composite Autonomic Scoring Scale results were abnormal in 93% of patients,
      and autonomic failure was severe in 20%"
    explanation: Quantitative autonomic testing showing that dysautonomia is near-universal,
      which is what the shared-antigen claim predicts.
  - reference: PMID:9443463
    reference_title: "Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No autoantibody correlated with autonomic dysfunction severity"
    explanation: The caveat on that account, quoted rather than paraphrased. The shared
      antigen explains why autonomic involvement occurs; it does not yet explain how severe
      it will be in a given patient.
  - reference: PMID:9443463
    reference_title: "Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast, 93% of the patients were seropositive for P/Q-type Ca2+ channel
      antibodies"
    explanation: Independent corroboration of the roughly 90% seropositivity rate from a
      separate cohort two decades earlier.
- name: Antigenic Modulation and Depletion of Active Zone Particles
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    The mechanism by which the antibody actually removes the channel, and the reason LEMS
    is a disease of channel number rather than of channel blockade. Bound divalent IgG
    cross-links the active zone particles - the freeze-fracture correlate of the
    presynaptic calcium channels - which aggregate into clusters and are then depleted from
    the membrane.

    The experiment that established this is a clean one. Divalent IgG and F(ab')2
    fragments aggregate and deplete the particles; monovalent Fab, which binds the same
    epitope but cannot cross-link two channels, does nothing. The pathogenic step is
    therefore cross-linking rather than binding, which is why an antibody that merely
    occupied the channel would not produce this disease.

    Removal is partly compensated: the terminal homeostatically upregulates other calcium
    channel types, which is a candidate reason the clinical severity is not simply
    proportional to antibody titre.
  molecular_functions:
  - preferred_term: calcium ion transmembrane transporter activity
    term:
      id: GO:0015085
      label: calcium ion transmembrane transporter activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: presynaptic active zone
    term:
      id: GO:0048786
      label: presynaptic active zone
  evidence:
  - reference: PMID:2853605
    reference_title: "Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Divalent LEMS IgG and F(ab')2 aggregated and depleted the active zone
      particles, whereas monovalent Fab had no effect"
    explanation: The cross-linking requirement, with its own internal negative control. This
      is the specific claim the node makes.
  - reference: PMID:2853605
    reference_title: "Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The active zone particles, normally arranged in double parallel rows, move
      closer together, form clusters, and are reduced in number"
    explanation: The morphological consequence, observed by quantitative freeze-fracture
      electron microscopy.
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The LEMS-mediated attack reduces the number of presynaptic calcium channels,
      disorganizes transmitter release sites, and results in the homeostatic upregulation
      of other calcium channel types"
    explanation: Independent confirmation in the passive-transfer model, and the source of
      the compensation claim in this node's description.
  downstream:
  - target: Reduced Calcium-Dependent Acetylcholine Release
    causal_link_type: DIRECT
    description: >-
      Fewer functional calcium channels at the active zone means less calcium entry per
      action potential, and transmitter release is a steeply nonlinear function of that
      entry.
- name: Reduced Calcium-Dependent Acetylcholine Release
  biological_scale: CELLULAR
  description: >-
    Loss of functional presynaptic calcium channels reduces calcium influx on
    depolarisation, and acetylcholine release is steeply calcium-dependent. The result is
    a quantal release deficit at an otherwise intact neuromuscular junction: the
    postsynaptic receptor, the acetylcholinesterase and the muscle are all normal.

    Two clinical signs follow directly from this and from nothing else. Sustained or
    repeated activity transiently accumulates presynaptic calcium, which partially
    overcomes the deficit - so strength and reflexes briefly improve after exertion, the
    reverse of myasthenia gravis. And on repetitive nerve stimulation the same physiology
    produces an increment at high frequency against a decrement at low frequency, which
    the cited review reports as a highly sensitive diagnostic pairing.
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: acetylcholine secretion, neurotransmission
    term:
      id: GO:0014055
      label: acetylcholine secretion, neurotransmission
    modifier: DECREASED
  downstream:
  - target: Neuromuscular and Autonomic Transmission Failure
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of decrement and increment upon repetitive nerve stimulation
      is also a highly sensitive diagnostic test"
    explanation: The electrophysiological signature of a presynaptic release deficit,
      quoted as the source states its diagnostic value.
- name: Neuromuscular and Autonomic Transmission Failure
  biological_scale: ORGANISM
  description: >-
    The clinical disorder: proximal weakness beginning in the upper legs, loss of tendon
    reflexes, and autonomic dysfunction. Progression can reach oculobulbar and, in severe
    cases, respiratory muscles.

    The ordering matters clinically. Weakness that starts in the thighs and spares the
    eyes early is the opposite of the ocular-onset pattern typical of myasthenia gravis,
    and it is a common reason LEMS is mistaken for a myopathy before serology is sent.
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disease
      characterized by proximal muscle weakness, loss of tendon reflexes, and autonomic
      dysfunction"
    explanation: The defining triad in the source's own words.
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle weakness usually starts in the upper legs and can progress to
      oculobulbar and in severe cases respiratory muscles"
    explanation: Establishes the proximal-onset pattern and the severe end of the range.

phenotypes:
- category: Neurological
  name: Proximal Muscle Weakness
  description: >-
    Fluctuating proximal weakness, characteristically beginning in the upper legs.
  phenotype_term:
    preferred_term: Proximal muscle weakness
    term:
      id: HP:0003701
      label: Proximal muscle weakness
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle weakness usually starts in the upper legs"
    explanation: The characteristic distribution.
- category: Neurological
  name: Loss of Tendon Reflexes
  description: >-
    Depressed or absent tendon reflexes, which may transiently return after sustained
    contraction - post-exercise facilitation. This is the sign that most reliably
    separates LEMS from myasthenia gravis at the bedside, because it follows from
    presynaptic physiology rather than from severity.
  phenotype_term:
    preferred_term: Hyporeflexia
    term:
      id: HP:0001265
      label: Hyporeflexia
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by proximal muscle weakness, loss of tendon reflexes, and
      autonomic dysfunction"
    explanation: Establishes areflexia as a defining rather than incidental feature.
- category: Neurological
  name: Autonomic Dysfunction
  description: >-
    Dysautonomia arising from the same P/Q-type channels in autonomic terminals. Dry
    mouth is the most commonly reported symptom; male sexual impotence is frequent enough
    to have earned a place in the tumour-prediction score.
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0002270
      label: Abnormality of the autonomic nervous system
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "P/Q-type voltage-gated calcium channels (VGCCs) localized in the presynaptic
      motor nerve terminal and in the autonomic nervous system are targeted by antibodies"
    explanation: Grounds the autonomic phenotype in the antigen's distribution rather than
      treating it as an unexplained association.

- category: Autonomic
  name: Dry Mouth
  description: >-
    Xerostomia, the commonest autonomic feature, and one of the direct consequences of the
    antigen being shared between motor and autonomic terminals.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Xerostomia
    term:
      id: HP:0000217
      label: Xerostomia
  evidence:
  - reference: PMID:9443463
    reference_title: "Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dry mouth (77%) and impotence (45% of men) were the most common symptoms"
    explanation: Direct quantitative support for the FREQUENT band (77%, within the 30-79%
      range), in a series of 30 patients with quantitative autonomic testing.
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Involvement of the autonomic nervous system is also likely and may cause a
      dry mouth; sometimes erectile dysfunction is also present in men"
    explanation: Names both autonomic phenotypes curated here in one sentence.

- category: Autonomic
  name: Erectile Dysfunction
  description: >-
    Male sexual impotence, autonomic in origin. Curated separately from its role as a
    DELTA-P scoring item, which is a different claim: this is the phenotype, that is its
    use as a tumour predictor.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Autonomic erectile dysfunction
    term:
      id: HP:0008652
      label: Autonomic erectile dysfunction
  evidence:
  - reference: PMID:9443463
    reference_title: "Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dry mouth (77%) and impotence (45% of men) were the most common symptoms"
    explanation: Direct quantitative support for the FREQUENT band, at 45% of men.
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Involvement of the autonomic nervous system is also likely and may cause a
      dry mouth; sometimes erectile dysfunction is also present in men"
    explanation: The autonomic attribution, which is what the HPO term used here specifies.
  - reference: PMID:21245427
    reference_title: "Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Age at onset, smoking behavior, weight loss, Karnofsky performance status,
      bulbar involvement, male sexual impotence, and the presence of Sry-like high-mobility
      group box protein 1 serum antibodies were independent predictors for SCLC in LEMS"
    explanation: Independent confirmation that the phenotype occurs in LEMS, in a cohort of
      219 patients across two countries.

- category: Neurological
  name: Bulbar Involvement
  description: >-
    Weakness of the muscles of chewing, swallowing and speech. Present in a substantial
    minority, prognostically important because it is one of the six DELTA-P items, and
    curated here because the entry's own snippets referred to it without annotating it.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle weakness usually starts in the upper legs and can progress to
      oculobulbar and in severe cases respiratory muscles"
    explanation: Bulbar progression as part of the natural history.
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Occasionally, there is weakness in the face and sometimes in muscles that
      allow for chewing, swallowing, and breathing"
    explanation: Names swallowing specifically, which is the phenotype bound here.

- category: Ophthalmological
  name: Ptosis
  description: >-
    Eyelid weakness, usually mild. Its interest is comparative: prominent ocular
    involvement points to myasthenia gravis, and it is the mildness of the ocular signs in
    LEMS that helps separate them.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  evidence:
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Like myasthenia gravis (MG), LEMS may also affect muscles of the eyelids,
      causing ptosis, and it occasionally affects muscles that move the eyes, resulting in
      diplopia, but these symptoms are usually mild"
    explanation: States the phenotype and, in the same sentence, the severity qualifier that
      makes it a discriminator from myasthenia gravis.

- category: Ophthalmological
  name: Diplopia
  description: >-
    Double vision from extraocular muscle weakness. Occasional and usually mild.
  phenotype_term:
    preferred_term: Diplopia
    term:
      id: HP:0000651
      label: Diplopia
  evidence:
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it occasionally affects muscles that move the eyes, resulting in diplopia,
      but these symptoms are usually mild"
    explanation: The phenotype with its frequency and severity qualifiers.

prevalence:
- population: United States national Veterans Affairs population
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.26
  rate_low: 0.26
  rate_high: 0.33
  notes: >-
    2.6 per 1,000,000 for confirmed cases and 3.3 per 1,000,000 including probable cases.
    The same study's crude prevalence estimates are higher (9.2 and 10.9 per 1,000,000);
    the point-prevalence figures are recorded here.
  evidence:
  - reference: PMID:27997683
    reference_title: "Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Point prevalence was estimated at 2.6 per 1,000,000 (confirmed cases) and 3.3
      per 1,000,000 (combined confirmed and probable cases)"
    explanation: The point-prevalence estimates quoted here, with their case definitions.

animal_models:
- name: LEMS IgG passive-transfer mouse
  species: Mouse
  publication: PMID:29125190
  description: >-
    Daily intraperitoneal injection of LEMS patient serum or IgG into mice for two to four
    weeks. The model matters because it settles the direction of causation: the disease
    transfers with the antibody alone, so the antibody is sufficient and the cellular
    immune response is not required.
  modeled_mechanisms:
  - target: Antigenic Modulation and Depletion of Active Zone Particles
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Passive transfer reproduces the channel loss and release-site disorganisation this
      node asserts, in an animal that never mounted the immune response itself.
    limitations: >-
      Passive transfer models the effector arm and nothing upstream of it. It cannot
      reproduce the paraneoplastic trigger, tolerance breakdown, or the natural history,
      and the antibody is supplied continuously rather than produced.
    readouts:
    - name: Presynaptic calcium channel number at the neuromuscular junction
      target: Antigenic Modulation and Depletion of Active Zone Particles
      direction: DECREASED
      interpretation: >-
        The channel depletion this node models, produced by transferred human IgG.
      evidence:
      - reference: PMID:29125190
        reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The LEMS-mediated attack reduces the number of presynaptic calcium
          channels, disorganizes transmitter release sites, and results in the homeostatic
          upregulation of other calcium channel types"
        explanation: The measured channel loss and release-site disorganisation.
    evidence:
    - reference: PMID:29125190
      reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "a passive-transfer animal model has been developed in mice, which can be
        created by daily intraperitoneal injections of LEMS patient serum or IgG into mice
        for 2-4 weeks"
      explanation: Establishes the model and its construction, which is what makes it
        informative for an antibody-effector node.

treatments:
- name: Amifampridine (3,4-Diaminopyridine)
  description: >-
    Potassium channel blocker that prolongs the presynaptic action potential, widening the
    window for calcium entry and so increasing acetylcholine release. It works downstream
    of the lesion without correcting it - the antibody is untouched.

    The efficacy trial used a randomised withdrawal design rather than a conventional
    placebo start, because the drug had been in use for thirty years without conclusive
    evidence and withholding it de novo was not acceptable. Patients stable on 3,4-DAP
    were tapered to placebo or continued: none of the 14 continued on drug deteriorated by
    more than 30% on timed up-and-go, against 72% of the 18 tapered to placebo.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amifampridine
      term:
        id: CHEBI:135948
        label: amifampridine
  target_mechanisms:
  - target: Reduced Calcium-Dependent Acetylcholine Release
    treatment_effect: ACTIVATES
    description: >-
      Increases release at the affected terminal by prolonging depolarisation. Curated as
      acting on the release node rather than on the antibody node, because it is
      symptomatic: it compensates for the deficit and does not reduce it.
  evidence:
  - reference: PMID:29280483
    reference_title: "3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "None of the 14 participants who received continuous 3,4-DAP had > 30%
      deterioration in 3TUG time versus 72% of the 18 who tapered to placebo (P <
      0.0001)"
    explanation: The primary efficacy result, with both arms and its denominators.
  - reference: PMID:29280483
    reference_title: "3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM)
      for 30 years despite the lack of conclusive evidence of efficacy"
    explanation: Marked PARTIAL because it is context rather than support - it records why
      a withdrawal design was needed, which is what makes the result interpretable.
- name: Tumour Treatment
  description: >-
    In paraneoplastic disease, treating the underlying small-cell lung carcinoma is part
    of treating the neurological disorder rather than a parallel concern. It is the only
    treatment in this entry that acts on the trigger rather than on the effector arm or
    the symptom, which is why it is curated separately from immunosuppression rather than
    bundled with it.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: tumour-directed therapy
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Small-Cell Lung Carcinoma Ectopic Antigen Expression and Anti-Tumour Immune Response
    treatment_effect: INHIBITS
    description: >-
      Removing or shrinking the tumour removes the source of the ectopically expressed
      antigen that drives the cross-reactive response. Applies only to the paraneoplastic
      form; in tumour-negative LEMS this treatment has no target.
    evidence:
    - reference: PMID:38494285
      reference_title: "Lambert-Eaton myasthenic syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment of the tumor as well as symptomatic treatment and
        immunosuppression can effectively control symptoms in the majority of patients"
      explanation: Names tumour treatment as one of the three arms that control the
        neurological symptoms, which is the claim this edge makes.
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rapid diagnosis is important because of the association with SCLC in 50%-60%
      of patients, which stresses the need for vigorous tumor screening after diagnosis"
    explanation: Why tumour screening, and therefore tumour treatment, is on the critical
      path in this disease rather than incidental to it.

- name: Immunosuppression
  description: >-
    Reduction of the pathogenic antibody, as opposed to compensating for its effect.
    Curated as acting on the antibody node rather than the release node, which is the
    distinction between it and amifampridine: one lowers the cause, the other works around
    it.

    The cached sources establish immunosuppression as an effective arm without specifying
    a regimen, so no specific agent is curated here. Corticosteroids, azathioprine, IVIG
    and plasma exchange are used in practice; adding them needs a reference in the cache
    that states the claim, which this entry does not yet have.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Immunosuppression
    term:
      id: NCIT:C15262
      label: Immunotherapy
  target_mechanisms:
  - target: Anti-P/Q-Type VGCC Autoantibody Production
    treatment_effect: INHIBITS
    description: >-
      Acts on production of the pathogenic autoantibody, upstream of the channel depletion
      and the release deficit.
    evidence:
    - reference: PMID:38494285
      reference_title: "Lambert-Eaton myasthenic syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment of the tumor as well as symptomatic treatment and
        immunosuppression can effectively control symptoms in the majority of patients"
      explanation: Establishes immunosuppression as an effective arm, which is what this
        edge asserts; the agent-level detail is deliberately not curated.
  evidence:
  - reference: PMID:29125190
    reference_title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LEMS is an autoimmune disorder caused by antibodies directed against the
      voltage-gated calcium channels that provide the calcium ion flux that triggers
      acetylcholine release at the neuromuscular junction"
    explanation: >-
      The rationale for an antibody-directed treatment. The antibody is the cause, so
      lowering it is disease-modifying in a way symptomatic treatment is not.

definitions:
- definition_type: PHENOTYPE_ALGORITHM
  name: DELTA-P score for small-cell lung carcinoma prediction in LEMS
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    A clinical score that allocates one point for each of a set of features present at or
    within three months of onset, to estimate the probability that a patient with LEMS has
    an underlying small-cell lung carcinoma and so to set the intensity of tumour
    screening.

    Seven independent predictors of small-cell lung carcinoma were identified: age at
    onset, smoking behaviour, weight loss, Karnofsky performance status, bulbar
    involvement, male sexual impotence, and SOX1 antibodies. The score built from them
    contains only six items, and the seventh is the one deliberately left out. SOX1
    serology is excluded, so the maximum score is 6 and the instrument is purely clinical
    - which is what the source means by calling it "the simple clinical DELTA-P score",
    and what makes it usable at the bedside before any antibody result returns.

    The six scored items are age at onset at least 50 years, smoking at diagnosis, weight
    loss of at least 5%, bulbar involvement, erectile dysfunction, and Karnofsky
    performance status below 70, each present at or within three months of onset. Several
    are the disease's own phenotypes, which is what makes the score a mechanism-adjacent
    instrument rather than a generic risk calculator: the paraneoplastic form declares
    itself partly through a more aggressive neurological presentation.
  validation_status:
    status: VALIDATED_AGAINST_GOLD_STANDARD
    rationale: >-
      Derived in a nationwide cohort of 107 Dutch patients and validated in a separate
      cohort of 112 British patients, with tumour status as the reference standard.
  evidence:
  - reference: PMID:21245427
    reference_title: "Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We derived a prediction score for SCLC in LEMS in a nationwide cohort of 107
      Dutch patients, and validated it in a similar cohort of 112 British patients"
    explanation: The derivation and validation cohorts, which is what the
      VALIDATED_AGAINST_GOLD_STANDARD status rests on.
  - reference: PMID:21245427
    reference_title: "Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Age at onset, smoking behavior, weight loss, Karnofsky performance status,
      bulbar involvement, male sexual impotence, and the presence of Sry-like high-mobility
      group box protein 1 serum antibodies were independent predictors for SCLC in LEMS"
    explanation: The seven independent predictors. Quoted because the distinction between
      these and the six scored items below is the thing most easily got wrong about this
      score - SOX1 appears here and not there.
  - reference: PMID:21245427
    reference_title: "Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A DELTA-P score was derived allocating 1 point for the presence of each of
      the following items at or within 3 months from onset: age at onset ≥ 50 years,
      smoking at diagnosis, weight loss ≥ 5%, bulbar involvement, erectile dysfunction, and
      Karnofsky performance status lower than 70"
    explanation: The six items that are actually scored, with SOX1 absent. This is the
      operative definition of the instrument.
  - reference: PMID:21245427
    reference_title: "Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A DELTA-P score of 0 or 1 corresponded to a 0% to 2.6% chance of SCLC,
      whereas scores of 4, 5, and 6 corresponded to chances of SCLC of 93.5%, 96.6%, and
      100%, respectively"
    explanation: The calibration, and independent confirmation that the maximum is 6 rather
      than 7.

differential_diagnoses:
- name: Myasthenia gravis
  description: >-
    The principal differential and the informative one. Both are autoimmune disorders of
    neuromuscular transmission, but the antigen sits on opposite sides of the synapse -
    postsynaptic acetylcholine receptor in myasthenia gravis, presynaptic calcium channel
    in LEMS. Separated by reflexes (lost in LEMS, preserved in myasthenia gravis), by the
    direction of the response to exertion, by autonomic involvement, and by the increment
    rather than decrement on high-frequency repetitive nerve stimulation.
- name: Inflammatory or metabolic proximal myopathy
  description: >-
    Shares the proximal, leg-predominant weakness that typically brings LEMS patients to
    attention. Distinguished by intact tendon reflexes, absent autonomic features, and
    normal repetitive nerve stimulation.

discussions:
- discussion_id: gap_antibody_negative_lems
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What accounts for the roughly one in ten patients with clinical and electrophysiological
    LEMS in whom P/Q-type VGCC antibodies are not detected?
  attaches_to:
  - pathophysiology#Anti-P/Q-Type VGCC Autoantibody Production
  rationale: >-
    The cited review reports antibody detection in about 90% of patients, which leaves a
    seronegative remainder that the entry's mechanism does not explain. The possibilities
    are not equivalent and they are not distinguished by the evidence curated here: assay
    insensitivity for low-titre or conformation-dependent antibodies; antibodies against a
    different presynaptic target not covered by the standard assay; or a genuinely distinct
    presynaptic disorder sharing the phenotype.

    The second possibility is not merely speculative. In a series of 20 patients, six had
    antibodies against synaptotagmin, a synaptic vesicle protein rather than a calcium
    channel, and three of those six showed no cross-reactivity with any VGCC subtype at
    all. So antibodies to non-channel presynaptic proteins do occur in LEMS, and can occur
    without accompanying channel antibodies - which is the seronegative case this gap is
    about. What is not established is how much of the seronegative remainder they account
    for, since that study predates current assays and was not designed to sample it.

    Note what this does not affect. Tumour screening is driven by the DELTA-P score, which
    is purely clinical and contains no serology at all, so a VGCC-seronegative patient
    enters that pathway with nothing missing. SOX1 antibodies are a separate marker of the
    paraneoplastic form and a different antigen entirely - a nuclear SCLC tumour antigen,
    not the presynaptic calcium channel - so seronegativity for VGCC says nothing about
    SOX1 status either.
  evidence:
  - reference: PMID:38494285
    reference_title: "Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These antibodies can be detected in about 90% of patients"
    explanation: Establishes the seronegative remainder this gap is about.
  - reference: PMID:8583238
    reference_title: "Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Six patients' sera (1 with small cell lung carcinoma (SCLC)) contained
      antibodies specifically recognizing the recombinant synaptotagmin on immunoblots"
    explanation: Antibodies to a non-channel presynaptic protein in LEMS, which is the
      second possibility this gap lists.
  - reference: PMID:8583238
    reference_title: "Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Three of 6 synaptotagmin-positive sera had cross-reactivity with N and/or Q
      subtypes of VGCC; the remaining 3 showed no cross-reactivity with VGCCs"
    explanation: The half of those sera with no channel reactivity at all - the closest
      thing in the cited literature to the seronegative case. PARTIAL because the study
      predates current assays and was not designed to quantify that remainder.
  proposed_experiments:
  - experiment_id: seronegative_lems_target_discovery
    name: Antigen discovery in seronegative clinically defined LEMS
    description: >-
      Screen serum from patients meeting clinical and electrophysiological criteria for
      LEMS but negative on standard P/Q-type VGCC radioimmunoassay against presynaptic
      terminal proteins, with passive transfer to test whether any candidate reproduces the
      release deficit.

notes: >-
  No GeneReviews chapter exists for this disease. The search "Lambert-Eaton
  GeneReviews[All Fields]" returns zero results. Expected - LEMS is an acquired autoimmune
  disorder with no Mendelian form.

  MONDO has an obsolete term for this concept, MONDO:0000287 "obsolete Lambert-Eaton
  myasthenic syndrome", alongside the live MONDO:0018556 bound here. A synonym-aware
  search returns both; a label-only search or taking the first hit would risk the obsolete
  one. Recorded because the same class of error - a term that exists but should not be
  used - has bitten this knowledge base before.

  There is deliberately NO genetic: section, and the reason is worth stating because the
  temptation is real. CACNA1A encodes the alpha-1A subunit of the P/Q-type channel this
  disease's antibodies attack, so the gene is easy to reach for. But LEMS is not a
  channelopathy: the gene is not mutated, the channel is not intrinsically defective, and
  an autoantibody removes a normal channel from a normal terminal. Every value available
  in RelationshipTypeEnum - CAUSATIVE, RISK_FACTOR, SUSCEPTIBILITY, MODIFIER, BIOMARKER,
  DISPUTED, UNKNOWN - would assert some genetic relationship to the disease, and none
  holds. Germline CACNA1A variants cause familial hemiplegic migraine, episodic ataxia
  type 2 and spinocerebellar ataxia 6; none of them is LEMS. The channel's identity is
  curated where it is true, on the antibody-target pathophysiology node.

  A first draft did include a genetic entry with relationship_type OTHER. Schema
  validation rejected it, because OTHER is not in the enum - and that rejection was
  correct for a better reason than the one it gave: there was no honest value to choose.

  PMID:41945880 was found during the literature search and deliberately not used. It is a
  randomised trial of amifampridine in MYASTHENIA GRAVIS, not LEMS - the same drug in the
  neighbouring disease. Citing it here would have been a subtle and hard-to-detect
  substitution, since the drug name and trial design both look right.

  Immunosuppression is curated without a named agent, deliberately. Corticosteroids,
  azathioprine, IVIG and plasma exchange are all standard practice, and the temptation is
  to list them. The cached sources establish immunosuppression as an effective arm without
  stating a regimen, and a treatment entry naming an agent whose evidence is not in the
  cache would be an assertion the entry cannot support. Adding them needs a guideline or
  trial reference fetched into the cache first.

  Frequency bands are assigned to two phenotypes only, and the asymmetry is deliberate.
  Dry mouth and erectile dysfunction carry FREQUENT because PMID:9443463 measured them
  directly in a series of 30 patients - 77% and 45% of men - so each band has its own
  quantitative snippet rather than an inferred one. The remaining phenotypes are left
  unbanded because the cited review describes the triad qualitatively. The numbers that
  review does give - 90% antibody positivity, 50-60% SCLC association - are a test
  characteristic and a comorbidity rate respectively, not phenotype frequencies, and are
  curated in the sections where they belong.

  Deep-research provenance, corrected. An earlier version of this note claimed that a
  validation section had been retro-fitted onto the claude_code report with just
  validate-research-reference. It had not. The recipe fails in this environment on TLS
  certificate verification when it reaches api.crossref.org, and the report carries neither
  a reference_validation frontmatter block nor a Reference Validation section. The intent
  was recorded as the outcome, which is exactly the error the evidence policy here exists
  to catch, so it is corrected rather than quietly removed.

  What is true about the provenance: the first round of curation cited nothing from the
  report, having assembled its references by direct PubMed search. The review round drew
  five PMID leads from the report's citation list (2853605, 18032743, 27997683, 29125190,
  31831596). Each was fetched with just fetch-reference, its real abstract read, and every
  snippet verified against the cache - so the report functioned as a lead generator and no
  claim rests on its summary of any paper.

references:
- reference: PMID:38494285
  title: "Lambert-Eaton myasthenic syndrome."
- reference: PMID:29280483
  title: "3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia."
- reference: PMID:21245427
  title: "Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS."
- reference: PMID:2853605
  title: "Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation."
- reference: PMID:18032743
  title: "SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome."
- reference: PMID:27997683
  title: "Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population."
- reference: PMID:29125190
  title: "Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads."
- reference: PMID:31831596
  title: "Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome."
- reference: PMID:9443463
  title: "Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates."
- reference: PMID:8583238
  title: "Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome."

📚

References & Deep Research

References

10

PMID:38494285

Lambert-Eaton myasthenic syndrome.

No top-level findings curated for this source.

PMID:29280483

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

No top-level findings curated for this source.

PMID:21245427

Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS.

No top-level findings curated for this source.

PMID:2853605

Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation.

No top-level findings curated for this source.

PMID:18032743

SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.

No top-level findings curated for this source.

PMID:27997683

Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.

No top-level findings curated for this source.

PMID:29125190

Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

No top-level findings curated for this source.

PMID:31831596

Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.

No top-level findings curated for this source.

PMID:9443463

Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates.

No top-level findings curated for this source.

PMID:8583238

Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Lambert-Eaton Myasthenic Syndrome (LEMS): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 41 citations 2026-08-22T00:09:02.563139

Lambert-Eaton Myasthenic Syndrome (LEMS): Comprehensive Research Report

1. Disease Information

Overview

Lambert-Eaton myasthenic syndrome (LEMS) is a rare, acquired autoimmune disorder of the presynaptic neuromuscular junction (NMJ). Autoantibodies directed against P/Q-type voltage-gated calcium channels (VGCCs) at the presynaptic motor nerve terminal impair calcium-dependent quantal release of acetylcholine (ACh), producing a clinical triad of proximal muscle weakness, hyporeflexia/areflexia, and autonomic dysfunction (NCBI StatPearls; Lancet Neurology 2011). LEMS occurs in two principal forms: a paraneoplastic form (~50–60% of cases, most commonly associated with small-cell lung cancer, SCLC) and a non-paraneoplastic (autoimmune) form associated with other autoimmune diseases and specific HLA haplotypes.

Key Identifiers

Database	Identifier
MONDO	MONDO:0018556 (EBI OLS)
ICD-10-CM	G70.81 (Lambert-Eaton syndrome in disease classified elsewhere) (ICD10Data.com)
Orphanet	Orphanet entry for LEMS (Orpha number 43393 per search result URL) (Orphanet)
OMIM	No dedicated Mendelian phenotype MIM number was located — LEMS is an acquired autoimmune disorder rather than a single-gene Mendelian disease, so it is not catalogued in OMIM the way a monogenic disorder would be. (Note: searches for candidate numbers 601991/600524/245550 did not confirm a LEMS-specific OMIM phenotype entry — 600524 resolves to RYK and 245550 to an unrelated "Lambert Syndrome"; this should be verified directly against a current OMIM query before citing a number in the KB.)
Wikidata	Q1756898 (Wikidata)

Synonyms

Lambert-Eaton syndrome; Eaton-Lambert syndrome; myasthenic syndrome (paraneoplastic); LEMS.

Evidence Source Note

Most published data on LEMS derive from aggregated clinical cohorts and registries (e.g., the European LEMS registry, Dutch-English DELTA-P cohort, US Veterans Affairs population studies) rather than individual EHR-level data, supplemented by case reports/series and passive-transfer mouse model studies establishing autoimmune causation.

2. Etiology

Disease Causal Factors

The proximate cause is autoantibody-mediated attack on presynaptic P/Q-type (CaV2.1) voltage-gated calcium channels, found in ~85–95% of patients (NEJM 1995; StatPearls). Divalent IgG antibodies cross-link VGCCs, causing clustering, internalization, and net reduction of functional channels at the presynaptic active zone, disrupting the calcium influx required for synaptic vesicle fusion and ACh release.

Two distinct triggering pathways converge on this final common mechanism: 1. Paraneoplastic (tumor-associated) LEMS: SCLC cells express functional VGCCs (ectopic neuroendocrine expression), and the anti-tumor immune response cross-reacts with neuronal VGCCs — molecular mimicry between tumor antigen and neuronal channel (Lancet Neurology 2011). 2. Non-tumor (autoimmune) LEMS: Occurs as a primary autoimmune disorder, often co-occurring with other autoimmune diseases (e.g., type 1 diabetes, thyroid autoimmunity), and is genetically predisposed by specific HLA haplotypes.

Risk Factors

Genetic: - HLA-B8, HLA-DR3, HLA-DQ2 haplotype (HLA-B8–DR3) present in ~65% of young non-tumor LEMS patients, indicating strong genetic susceptibility in the autoimmune subtype (Gavin Publishers). - Mouse models carrying CACNA1A mutations (the gene encoding the P/Q-type VGCC α1A subunit) recapitulate LEMS-like phenotypes, supporting the channel's centrality to disease mechanism (not as a Mendelian cause of human LEMS, but validating the antigenic target) (MalaCards).

Environmental/Clinical: - Age ≥50 at onset, current/former smoking, weight loss ≥5%, bulbar involvement, erectile dysfunction, and Karnofsky performance status <70 are DELTA-P score components strongly predicting underlying SCLC (PMID:21245427). - Smoking history is a major risk factor via its link to SCLC.

Protective Factors: No specific genetic or environmental protective factors were identified in the literature reviewed; this is an area of relative evidence gap for LEMS specifically.

Gene-Environment Interactions

The paraneoplastic pathway represents a gene(HLA)-independent but antigen-driven interaction: tumor VGCC expression (an "environmental"/somatic trigger) interacts with pre-existing immune surveillance machinery to generate cross-reactive autoimmunity. In non-tumor LEMS, HLA genotype appears to be the dominant susceptibility factor without a clear precipitating environmental trigger identified in the literature surveyed.

3. Phenotypes

Core Clinical Triad

Proximal muscle weakness — symmetric, predominantly affecting proximal lower extremities (difficulty rising from a chair, climbing stairs), progressing proximal→distal and potentially to oculobulbar and respiratory muscles in severe disease (StatPearls). Suggested HPO: HP:0003701 (Proximal muscle weakness).
Hyporeflexia/Areflexia with post-exercise facilitation — deep tendon reflexes diminished or absent, with transient improvement after sustained voluntary contraction in 1/3–2/3 of patients (a hallmark distinguishing feature). Suggested HPO: HP:0001265 (Hyporeflexia) / HP:0001284 (Areflexia).
Autonomic dysfunction — present in 80–96% of patients (37% in one Japanese cohort), including xerostomia (dry mouth), constipation, orthostatic lightheadedness, urinary symptoms, and erectile dysfunction (MedLink Neurology). Suggested HPO: HP:0002458 (Xerostomia... note: verify exact term), HP:0002019 (Constipation), HP:0012647 (Abnormal autonomic nervous system physiology).

Additional Phenotypes

Ocular/bulbar involvement: At least one-third of patients develop ptosis, diplopia, dysarthria, or dysphagia — generally milder and later-onset than in myasthenia gravis (MedLink Neurology). Suggested HPO: HP:0000508 (Ptosis), HP:0000651 (Diplopia), HP:0002015 (Dysphagia).
Post-exertional facilitation of strength — transient increase in muscle strength/CMAP amplitude following brief exercise, a functional-testing correlate of the presynaptic defect.
Autonomic subtype breakdown (autonomic reflex screen abnormalities): sudomotor abnormalities most frequent (83%), followed by cardiovagal (75%) and adrenergic (37%) (search result synthesis, Autonomic dysfunction studies).

Phenotype Characteristics

Age of onset: Typically >40 years old (mean presentation age for paraneoplastic LEMS ~58 years); can occur at any age.
Progression: Chronic and typically progressive, particularly in SCLC-associated LEMS; non-tumor LEMS tends to have a more stable/indolent course.
Severity/course: Variable; respiratory muscle involvement is possible in severe cases and represents a "myasthenic crisis"-like presentation.

Quality of Life Impact

Long-term follow-up studies show reduced quality of life correlating with residual weakness and autonomic symptom burden, though detailed QoL instrument data (EQ-5D/SF-36-specific scores) were not retrieved in this search; a 2020 Neurology study specifically addressed long-term follow-up, QoL, and survival (PMID:31831596; Neurology 2020).

4. Genetic/Molecular Information

Causal Genes / Antigenic Targets

LEMS is not a monogenic Mendelian disorder — there is no single causal germline gene. Instead, the disease target is the gene product of: - CACNA1A (P/Q-type VGCC α1A pore-forming subunit, CaV2.1) — the primary autoantigen (targeted in ~85–95% of patients). - CACNB2 (voltage-dependent calcium channel beta-2 subunit) — referenced as a related calcium channel subunit gene in OMIM (entry 600003), though its direct disease relevance to LEMS specifically (versus channel biology generally) should be confirmed. - N-type (CaV2.2) and Q-type VGCCs are also targeted by a subset of LEMS antibodies (PMID:7891097). - Synaptotagmin — an active-zone protein that physically associates with N-type/P-Q-type calcium channels, identified as a co-target autoantigen (ScienceDirect; PMID:8583238). - SOX1* (SRY-box transcription factor 1) — a paraneoplastic marker antibody (anti-glial nuclear antibody/AGNA), found in ~43% of LEMS-SCLC patients, with high specificity for occult/associated SCLC; used clinically to flag patients needing closer cancer surveillance (JCO 2008; PMID:18032743).

Pathogenic "Variants" (Antibody Classification, Not Germline Variants)

Since LEMS pathology is antibody-driven rather than variant-driven: - No ACMG/AMP pathogenic variant classification applies to a causal germline gene. - Antibody isotype/valency matters mechanistically: divalent IgG and F(ab')2 fragments cross-link and deplete VGCCs, whereas monovalent Fab fragments have no pathogenic effect — demonstrating that channel cross-linking/internalization, not simple channel blockade, is the operative mechanism (Ann Neurol 1988; PMID:2853605).

Functional Consequences

Antibody-mediated cross-linking of active-zone VGCC particles → clustering and internalization → reduced functional channel density at the presynaptic membrane → decreased calcium influx during depolarization → reduced quantal ACh release → impaired neuromuscular transmission (StatPearls; NEJM 1995).

Modifier / Contributing Genes

HLA class I/II alleles (HLA-B8, HLA-DR3, HLA-DQ2) function as susceptibility/modifier loci for the non-tumor autoimmune subtype rather than direct causal genes.

Chromosomal Abnormalities

None reported; LEMS is not associated with structural chromosomal anomalies.

5. Environmental Information

Environmental/Lifestyle Factors

Smoking is strongly linked as a risk factor via its causal relationship to SCLC, the dominant paraneoplastic trigger, and is one of the six DELTA-P score variables predicting tumor association (PMID:21245427).

Infectious Agents

No infectious trigger has been established in the literature reviewed; LEMS is not classified as an infection-associated autoimmune disease in current evidence.

6. Mechanism / Pathophysiology

Causal Chain (Trigger → Manifestation)

Trigger: SCLC ectopic VGCC expression (paraneoplastic) OR primary autoimmune predisposition (HLA-linked, non-tumor).
Autoantibody generation: Polyclonal IgG antibodies against P/Q-type (and N-type) VGCCs and associated active-zone proteins (synaptotagmin).
Molecular target engagement: Divalent IgG cross-links VGCC "active zone particles" arranged in the normal double-parallel-row architecture of the presynaptic active zone.
Ultrastructural consequence: Freeze-fracture electron microscopy shows active-zone particles move closer together, aggregate into clusters, and are reduced in overall number — demonstrated in both human LEMS tissue and the mouse passive-transfer model (PNAS 1983; Ann Neurol 1987).
Cellular consequence: Reduced presynaptic calcium influx upon nerve terminal depolarization.
Physiological consequence: Decreased probability and quantity of synaptic vesicle fusion/ACh quantal release at the neuromuscular junction (and at autonomic cholinergic synapses, explaining the autonomic phenotype).
Clinical manifestation: Fluctuating proximal weakness, hyporeflexia (with post-tetanic potentiation), and autonomic symptoms.

Molecular Pathways

Presynaptic calcium signaling / SNARE-mediated vesicle fusion pathway disruption at the neuromuscular junction active zone.
GO Biological Process suggestions: GO:0006816 (calcium ion transport), GO:0007269 (neurotransmitter secretion), GO:0017156 (calcium ion regulated exocytosis).

Cellular Processes

Impaired calcium-triggered exocytosis of ACh-containing synaptic vesicles.
Antibody-mediated antigenic modulation (cross-linking → internalization) of a cell-surface ion channel — a mechanism shared conceptually with myasthenia gravis (AChR antibodies) but acting presynaptically rather than postsynaptically.

Protein Dysfunction

Loss of function of P/Q-type VGCC at the membrane (via antibody-driven internalization/clustering, not a structural channel mutation) — this is a gain-of-autoimmune-attack / loss-of-channel-availability mechanism rather than an intrinsic protein misfolding process.

Immune System Involvement

LEMS is a humoral (antibody-mediated) autoimmune disease. The paraneoplastic form specifically exemplifies tumor-neural cross-reactivity (molecular mimicry): SCLC neuroendocrine cells aberrantly express functional VGCCs, and an anti-tumor humoral response generates antibodies that cross-react with neuronal VGCCs at the NMJ.

Cell Types Involved

Motor neuron presynaptic terminal (site of pathology). Suggested CL term: CL:0000100 (motor neuron), presynaptic terminal component.
Autonomic cholinergic neurons (explaining dysautonomia).
SCLC neuroendocrine tumor cells (source of cross-reactive antigen in paraneoplastic cases).
Plasma cells/B lymphocytes producing the pathogenic IgG.

Molecular Profiling

Antibody profiling (VGCC-P/Q antibody titer, SOX1 antibody) serves as the primary "molecular" diagnostic readout rather than transcriptomic/proteomic tissue profiling, which is not a standard part of LEMS workup per the literature reviewed.

7. Anatomical Structures Affected

Organ/System Level

Primary: Peripheral nervous system — neuromuscular junction (presynaptic motor nerve terminal) and autonomic nervous system synapses.
Secondary: Respiratory system (in severe/crisis presentations with respiratory muscle weakness); lung (as the site of the associated SCLC in paraneoplastic cases — not itself a target of the autoimmune process, but the source antigen reservoir).
Body systems: Neuromuscular, autonomic (cardiovascular, gastrointestinal, genitourinary, sudomotor).

Tissue/Cell Level

Presynaptic active zone of the motor nerve terminal (specific structural target of antibody attack).
Suggested UBERON: UBERON:0001133 (neuromuscular junction), UBERON:0000010 (peripheral nervous system).

Subcellular Level

Presynaptic plasma membrane active zone particles (VGCC clusters) — GO Cellular Component: GO:0048786 (presynaptic active zone).

Localization

Bilateral/symmetric distribution of weakness (proximal legs > arms); no lateralization reported.

8. Temporal Development

Onset

Typically adult-onset (>40 years); mean presentation age for SCLC-associated LEMS ~58 years. Onset is generally insidious/subacute.

Progression

SCLC-associated LEMS: More rapidly progressive weakness at diagnosis (interestingly, paraneoplastic LEMS is associated with better tumor prognosis relative to SCLC without LEMS, likely reflecting enhanced anti-tumor immunity — see Prognosis).
Non-tumor LEMS: More indolent/chronic course; can be relapsing or slowly progressive over years.
No formal staging system was identified analogous to cancer staging; disease severity is typically tracked via clinical strength scores and quantitative MRC/QMG-type measures plus electrodiagnostic parameters.

Patterns

Post-exercise/post-tetanic facilitation is a distinctive short-term (seconds-to-minutes) reversible pattern — a key diagnostic and pathophysiologic hallmark distinguishing LEMS from myasthenia gravis (which shows fatigable weakness rather than facilitation).
Immunotherapy or tumor treatment can induce remission or substantial improvement.

9. Inheritance and Population

Epidemiology

Prevalence: Estimated 1/250,000–1/333,300 worldwide; other estimates cite ~3.42 per million — roughly 20-fold rarer than AChR-antibody-positive myasthenia gravis (search synthesis).
Turkey nationwide EHR study (2024): annual incidence 0.09–0.30 per million; 2024 prevalence 1.11 per million (PMC12414958).
US Veterans Affairs study: point prevalence 2.6/million (confirmed cases), 3.3/million (confirmed + probable) (PMID:27997683).
LEMS is likely markedly under-diagnosed in SCLC patients per a recent real-world claims data analysis (PMC12575191).

Inheritance Pattern

Not Mendelian — LEMS is an acquired autoimmune disease. There is no classic inheritance pattern (AD/AR/X-linked); susceptibility is polygenic/immunogenetic (HLA-associated) for the non-tumor subtype.
Penetrance/expressivity/anticipation/mosaicism/founder effects: Not applicable in the Mendelian sense, given the acquired autoimmune nature of the disease.

Population Demographics

Sex ratio: Some sources note a slight male predominance overall, driven by the male predominance of SCLC in the paraneoplastic subgroup, while non-tumor LEMS may show a more even or female-leaning distribution — specific ratios were not precisely quantified in the sources retrieved and would benefit from a targeted follow-up search of registry data.
Age distribution: Bimodal tendency — younger-onset patients more often HLA-B8/DR3-positive non-tumor LEMS; older-onset (>50) patients more likely to have SCLC-associated LEMS (per DELTA-P score design).

10. Diagnostics

Clinical/Electrodiagnostic Tests

Electrophysiologic triad: (1) low compound muscle action potential (CMAP) amplitude at rest; (2) decrement on low-frequency (2–3 Hz) repetitive nerve stimulation (RNS); (3) incremental response (facilitation) ≥ ~60–100% on high-frequency (30–50 Hz) RNS or after brief (10-second) voluntary exercise (StatPearls).
Autonomic testing: Quantitative sudomotor axon reflex test (QSART) and broader autonomic reflex screen showing sudomotor (83%), cardiovagal (75%), and adrenergic (37%) abnormalities.

Antibody/Biomarker Testing

P/Q-type VGCC antibody (positive in 85–95% of patients) — the primary serologic diagnostic test.
N-type VGCC antibody — supportive in a subset.
SOX1 (AGNA) antibody — supportive marker with high specificity for underlying SCLC (43% of LEMS-SCLC patients).

Imaging / Cancer Screening

CT chest and, per some guidelines, FDG-PET/CT for SCLC screening, given the high paraneoplastic association.
DELTA-P score (age ≥50, smoking, weight loss ≥5%, bulbar involvement, erectile dysfunction, Karnofsky <70) stratifies tumor risk: score 0–1 → 0–2.6% SCLC probability; score 4–6 → 93.5–100% probability (AUC 94.4–94.6%) (PMID:21245427).

Differential Diagnosis

Myasthenia gravis (postsynaptic, fatigable rather than facilitating weakness, prominent early ocular/bulbar involvement), congenital myasthenic syndromes, botulism, other paraneoplastic neurological syndromes, chronic inflammatory demyelinating polyneuropathy (for the areflexia component).

Screening

No population-based newborn or carrier screening applies (non-genetic/acquired disease); the relevant "screening" paradigm is secondary cancer screening in patients presenting with LEMS symptoms, and conversely, closer surveillance/testing of SCLC patients for LEMS symptoms (an active area of clinical trial investigation, e.g., NCT07075627 examining LEMS incidence in newly diagnosed SCLC).

11. Outcome/Prognosis

Survival

Non-tumor LEMS (NT-LEMS): Normal life expectancy/survival compared to the general population.
SCLC-associated LEMS: Counterintuitively, patients with SCLC-LEMS show improved tumor survival compared to SCLC patients without LEMS, even after correcting for tumor stage — attributed to a more robust underlying anti-tumor immune response (PMC7324357; Nature Sci Rep 2020).
Early bulbar involvement, weight loss, and DELTA-P score did not significantly affect survival specifically within the SCLC-LEMS subgroup (Neurology 2020).

Morbidity/Function

Long-term follow-up shows persistent, though often treatable, weakness and autonomic symptom burden affecting quality of life; specific validated QoL instrument scores were not retrieved in this pass.

Prognostic Factors

Presence/absence of SCLC is the dominant prognostic determinant.
The DELTA-P score is the principal validated prognostic/predictive tool for tumor association (not survival per se within the SCLC-LEMS group).

12. Treatment

Symptomatic (Neuromuscular Transmission-Enhancing) Therapy

Amifampridine (3,4-diaminopyridine, 3,4-DAP) — first-line therapy, FDA-approved. Mechanism: blocks presynaptic voltage-gated potassium channels, prolonging nerve terminal action potential duration → increased presynaptic calcium influx → increased ACh release (PMC8464094 meta-analysis). Randomized controlled trials show significant efficacy at doses ≤80 mg/day with minimal adverse effects; FDA approved a dose increase to 100 mg/day (adults and pediatric patients >45 kg) on May 30, 2024 (regulatory filing).
Brand name Firdapse (amifampridine phosphate) — approved 2018 for adults, with a pediatric indication extension.
Ruzurgi (amifampridine, Jacobus Pharmaceutical) was approved in 2019 for pediatric patients (ages 6–17) but was subsequently invalidated following litigation brought by Catalyst Pharmaceuticals over marketing exclusivity.
NCIT term suggestion: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bound to amifampridine (specific CHEBI/NCIT ID to be verified).
Pyridostigmine (acetylcholinesterase inhibitor) — adjunctive symptomatic therapy, often combined with amifampridine.

Immune-Modulating Therapy

Short-term/rapid: IVIG (preferred first-line immunomodulation, improvement within 2–4 weeks) or plasma exchange (plasmapheresis) — used for crisis management or rapid symptom control.
Long-term immunosuppression: Corticosteroids (prednisone) plus steroid-sparing agents — azathioprine (first-line steroid-sparing agent per guideline), with mycophenolate mofetil, cyclosporine, tacrolimus, or rituximab as alternatives (Guideline for management of myasthenic syndromes, PMC10752078).

Oncologic Treatment (Paraneoplastic Cases)

Treatment of the underlying SCLC (chemotherapy ± radiotherapy ± immunotherapy per standard oncologic protocols) often improves LEMS symptoms independent of directed immunotherapy.

Treatment Outcomes

Amifampridine shows strong RCT-supported efficacy with a favorable safety profile at approved doses; principal adverse effects include paresthesias and, at higher doses, seizure risk (a known class effect of aminopyridines).

Experimental/Emerging

Calcium-channel gating modifiers combined with amifampridine (Firdapse) have shown in animal studies the ability to restore neuromuscular transmission to near-normal levels — still preclinical/experimental, not yet in human trials per the source reviewed (MDA Research).

13. Prevention

No primary prevention strategy exists for LEMS given its autoimmune/paraneoplastic etiology. The principal actionable "prevention" measure identified in the literature is: - Smoking cessation as a general SCLC risk-reduction strategy (indirect prevention of the paraneoplastic trigger). - Secondary prevention via active cancer surveillance: Patients diagnosed with LEMS without an initial cancer finding should undergo structured, repeated screening (e.g., using SOX1 antibody status and DELTA-P risk stratification) for at least 1–2 years, since occult SCLC frequently emerges after the neurological presentation.

14. Other Species / Natural Disease

Naturally occurring LEMS-like disease in companion animals or wildlife: No confirmed naturally occurring veterinary LEMS analog was identified in this search. This appears to be a genuine gap — unlike other neuromuscular disorders (e.g., canine myasthenia gravis), a natural LEMS phenocopy in domestic species is not well documented in the literature surveyed.
CACNA1A mutant mice: Mice carrying spontaneous or engineered CACNA1A mutations develop a LEMS-like phenotype, supporting the channel's mechanistic centrality, though this is a genetic/induced model rather than naturally occurring disease (MalaCards).

15. Model Organisms

Passive-Transfer Mouse Model (the flagship LEMS model)

Method: Daily intraperitoneal injection of purified human LEMS patient IgG (or serum) into mice for 2–4 weeks reproduces the electrophysiological and ultrastructural features of human LEMS (PMC5790601; PMID:29125190).
Historical foundation: First demonstrated by Lang et al. (PNAS 1983) — passive transfer of human LEMS IgG to mice depletes presynaptic membrane active zones, establishing the autoimmune basis of the disease (PNAS 1983).
Phenotype recapitulation: High fidelity — freeze-fracture EM shows the same active-zone particle depletion/clustering seen in human LEMS nerve terminal biopsies; immunoelectron microscopy localizes IgG directly to the motor end-plate (Ann Neurol 1987).
Mechanistic insight from the model: Divalent IgG/F(ab')2 fragments are pathogenic (cross-link and deplete channels); monovalent Fab fragments are not — demonstrating that channel cross-linking, not simple antigen binding, drives pathology (PMID:2853605).
Applications: Used to test therapeutic candidates, including the calcium-channel gating modifier + amifampridine combination noted above.
Limitations: A passive-transfer/induced model (dependent on continual antibody administration) rather than a spontaneous autoimmune model; does not fully model the chronic B-cell-driven autoimmune process or paraneoplastic tumor-antigen cross-reactivity initiation.

Genetic Models

CACNA1A-mutant mice — used as a genetic complement to the passive-transfer model, supporting the channel's causal role in the LEMS phenotype.

Summary of Suggested Ontology Terms for Curation

Category	Suggested Term(s)
Disease	MONDO:0018556
Genes	CACNA1A (hgnc gene for P/Q-type VGCC α1A), CACNB2
Phenotypes	HP terms for proximal muscle weakness, hyporeflexia/areflexia, xerostomia, constipation, ptosis, diplopia, dysphagia, autonomic dysfunction (exact HP IDs should be verified via OAK/HPO browser lookup before curation, per dismech SOP)
GO Biological Process	GO:0007269 (neurotransmitter secretion), GO:0017156 (calcium-ion-regulated exocytosis), GO:0006816 (calcium ion transport)
GO Cellular Component	GO:0048786 (presynaptic active zone)
Cell Types	CL:0000100 (motor neuron)
UBERON	UBERON:0001133 (neuromuscular junction)
Treatment (NCIT)	NCIT:C15986 (Pharmacotherapy) + therapeutic_agent for amifampridine

Ask OpenScientist

OpenScientist Report

Definitions

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Lambert-Eaton Myasthenic Syndrome (LEMS): Comprehensive Research Report

1. Disease Information

Overview

Key Identifiers

Synonyms

Evidence Source Note

2. Etiology

Disease Causal Factors

Risk Factors

Gene-Environment Interactions

3. Phenotypes

Core Clinical Triad

Additional Phenotypes

Phenotype Characteristics

Quality of Life Impact

4. Genetic/Molecular Information

Causal Genes / Antigenic Targets

Pathogenic "Variants" (Antibody Classification, Not Germline Variants)

Functional Consequences

Modifier / Contributing Genes

Chromosomal Abnormalities

5. Environmental Information

Environmental/Lifestyle Factors

Infectious Agents

6. Mechanism / Pathophysiology

Causal Chain (Trigger → Manifestation)

Molecular Pathways

Cellular Processes

Protein Dysfunction

Immune System Involvement

Cell Types Involved

Molecular Profiling

7. Anatomical Structures Affected

Organ/System Level

Tissue/Cell Level

Subcellular Level

Localization

8. Temporal Development

Onset

Progression

Patterns

9. Inheritance and Population

Epidemiology

Inheritance Pattern

Population Demographics

10. Diagnostics

Clinical/Electrodiagnostic Tests

Antibody/Biomarker Testing

Imaging / Cancer Screening

Differential Diagnosis

Screening

11. Outcome/Prognosis

Survival

Morbidity/Function

Prognostic Factors

12. Treatment

Symptomatic (Neuromuscular Transmission-Enhancing) Therapy

Immune-Modulating Therapy

Oncologic Treatment (Paraneoplastic Cases)

Treatment Outcomes

Experimental/Emerging

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Passive-Transfer Mouse Model (the flagship LEMS model)